Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G2 cell cycle arrest

Journal of Virology

Volumn 74, Issue 17, 2000, Pages 8159-8165

  Sherman, M P ^a   De Noronha, C M C ^a   Pearce, D ^a   Greene, W C ^a  

^a GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; LEUCINE;

ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; CELL CYCLE G2 PHASE; CELL DEATH; COMPLEX FORMATION; DIMERIZATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; STEM CELL; TARGET CELL; TRANSCRIPTION REGULATION; VIRUS ACTIVATION; VIRUS GENOME; VIRUS REPLICATION;

AMINO ACID SEQUENCE; CELL LINE; G2 PHASE; GENE PRODUCTS, VPR; HIV-1; HUMANS; LEUCINE ZIPPERS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NUCLEAR RECEPTOR COACTIVATOR 2; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, GLUCOCORTICOID; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 0033882196     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.17.8159-8165.2000     Document Type: Article

References (64)

1. The HIV-1 Vpr co-activator induces a conformational change in TFIIB
2. The human immunodeficiency virus type 1 Vpr transactivator: Cooperation with promoter-bound activator domains and binding to TFIIB
3. HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B
4. 2 accumulation by a mechanism which differs from DNA damage checkpoint control
5. Glucocorticoid-mediated repression of NFkappaB activity in endothelial cells does not involve induction of IkappaBalpha synthesis
6. Human immunodeficiency virus vpr product is a virion-associated regulatory protein
7. Identification of HIV-1 vpr product and function
8. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes
9. Structure and specificity of nuclear receptor-coactivator interactions
10. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation
11. HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator
12. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors
13. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM)
14. Human immunodeficiency virus type 1 vpr protein transactivation function: Mechanism and identification of domains involved
15. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway
16. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import
17. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo
18. Cell cycle- and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines
19. 2 phase of the cell cycle by inhibiting p34(cdc2) activity
20. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
21. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells
22. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
23. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors
24. Human immunodeficiency virus type 1 (HIV-1) Vpr functions as an immediate-early protein during HIV-1 infection
25. Characterization of HIV-1 vpr nuclear import: Analysis of signals and pathways
26. 2 + M phase of the cell cycle
27. New twists in gene regulation by glucocorticoid receptor: Is DNA binding dispensable?
28. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor
29. The p6(gag) domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles
30. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1
31. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency
32. Steroid receptor heterodimerization demonstrated in vitro and in vivo
33. Steroid receptor transcriptional synergy is potentiated by disruption of the DNA-binding domain dimer interface
34. 4 in p6(gag) is important for Vpr incorporation into human immunodeficiency virus type 1 particles
35. Structural studies of synthetic peptide fragments derived from the HIV-1 Vpr protein
36. Nuclear import, virion incorporation, and cell cycle arrest/ differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr
37. Hydrocortisone and some other hormones enhance the expression of HTLV-III
38. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation
39. Nonsense mutations in the vpr gene of HIV-1 during in vitro virus passage and in HIV-1 carrier-derived peripheral blood mononuclear cells
40. Incorporation of Vpr into human immunodeficiency virus type 1 virions: Requirement for the p6 region of gag and mutational analysis
41. Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents
42. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex
43. 2 by inhibiting the activation of p34(cdc2)-cyclin B
44. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product
45. DNA binding of the glucocorticoid receptor is not essential for survival
46. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection
47. Multiple receptor interaction domains of GRIP1 function in synergy
48. NMR structure of the (52-96) C-terminal domain of the HIV-1 regulatory protein Vpr: Molecular insights into its biological functions
49. Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1
50. Effects of RU486 on HIV-1 replication
51. Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells
52. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation
53. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages
54. Co-activators and corepressors in the integration of transcriptional responses
55. Evolution of the primate lentiviruses: Evidence from vpx and vpr
56. HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection
57. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat
58. Characterization of a leucine-zipper-like domain in Vpr protein of human immunodeficiency virus type 1
59. Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells
60. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: Role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation
61. Maintenance of an intact human immunodeficiency virus type 1 vpr gene following mother-to-infant transmission
62. Human immunodeficiency virus vpr gene encodes a virion-associated protein
63. Biochemical mechanism of HIV-1 Vpr function: Specific interaction with a cellular protein
64. Biochemical mechanism of HIV-1 Vpr function: Oligomerization mediated by the N-terminal domain